583.24
Regeneron Pharmaceuticals Inc stock is traded at $583.24, with a volume of 655.36K.
It is down -0.38% in the last 24 hours and up +1.72% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$585.48
Open:
$587.59
24h Volume:
655.36K
Relative Volume:
0.65
Market Cap:
$60.76B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.70
EPS:
39.6877
Net Cash Flow:
$3.56B
1W Performance:
+3.73%
1M Performance:
+1.72%
6M Performance:
+1.83%
1Y Performance:
-41.44%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.24 | 62.05B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
410.28 | 103.30B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
459.58 | 59.25B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
ARGX
Argen X Se Adr
|
797.35 | 48.22B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
341.62 | 37.84B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
Jun-30-25 | Downgrade | Argus | Buy → Hold |
May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
May-14-25 | Upgrade | Citigroup | Neutral → Buy |
Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jan-16-25 | Downgrade | UBS | Buy → Neutral |
Dec-10-24 | Resumed | BofA Securities | Underperform |
Nov-15-24 | Initiated | Wolfe Research | Outperform |
Nov-14-24 | Initiated | Citigroup | Neutral |
Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Mar-12-24 | Initiated | Bernstein | Outperform |
Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
Aug-21-23 | Reiterated | Oppenheimer | Perform |
Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
Jun-06-22 | Initiated | Jefferies | Underperform |
May-23-22 | Initiated | SVB Leerink | Outperform |
Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-09-21 | Resumed | Wells Fargo | Overweight |
Dec-07-21 | Resumed | Cowen | Market Perform |
Dec-06-21 | Initiated | Goldman | Buy |
Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
Jun-29-21 | Initiated | H.C. Wainwright | Buy |
Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
Apr-08-20 | Initiated | The Benchmark Company | Hold |
Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
Feb-27-20 | Initiated | Barclays | Overweight |
Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
Feb-11-20 | Upgrade | Argus | Hold → Buy |
Dec-24-19 | Initiated | Raymond James | Mkt Perform |
Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Nov-12-19 | Initiated | SunTrust | Hold |
Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc. - MarketBeat
Galderma Punches Above Its Weight Against Dermatology Goliaths - insights.citeline.com
Regeneron Pharmaceuticals (REGN): Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals - simplywall.st
Strategies to average down on Regeneron Pharmaceuticals Inc.2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Regeneron (REGN) Projects $83 Million R&D Charge in Q3 2025 - GuruFocus
Regeneron expects $83 million IPR&D charge in third quarter 2025 results - Investing.com
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Earnings Miss & Advanced Technical Signal Analysis - newser.com
Can trapped investors hope for a rebound in Regeneron Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. stock resilient to inflationQuarterly Market Review & Verified Technical Trade Signals - newser.com
111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Published on: 2025-10-06 01:04:19 - newser.com
Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why pension funds invest in Regeneron Pharmaceuticals Inc. (RGO) stock2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Applying Elliott Wave Theory to Regeneron Pharmaceuticals Inc.Weekly Stock Recap & Accurate Buy Signal Alerts - newser.com
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Why Regeneron (REGN) Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results - simplywall.st
Mirae Asset Global Investments Co. Ltd. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Robeco Institutional Asset Management B.V. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Financial Corp Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts - Proactive financial news
Forecasting Regeneron Pharmaceuticals Inc. price range with options data2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Greenwood Capital Associates LLC Acquires 4,419 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron’s 8% Weekly Surge Signal a Shift After New FDA Drug Approval? - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Cut by Greenleaf Trust - MarketBeat
Applying chart zones and confluence areas to Regeneron Pharmaceuticals Inc.Analyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Feds Eye Partial Pretrial Ruling In Regeneron FCA Case - Law360
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management - Yahoo Finance
Formycon secures settlement and license agreement with Regeneron - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough - Insider Monkey
Q3 Earnings Forecast for REGN Issued By Leerink Partnrs - MarketBeat
Regeneron (REGN) Gets a Buy from Leerink Partners - The Globe and Mail
Hudson Value Partners LLC Acquires Shares of 759 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron is giving away sequencing “for free”, with Alison Fenney - pharmaphorum
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron - MarketScreener
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 6.9%Here's Why - MarketBeat
Red Biotechnology Market Size, Analysis, Trends | Leading - openPR.com
Leerink Partnrs Analysts Lower Earnings Estimates for REGN - MarketBeat
Generali Investments CEE investicni spolecnost a.s. Acquires 540 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PGGM Investments Acquires 51,900 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 - Insider Monkey
What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity? - MSN
Regeneron: Growth Catalysts Incoming (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. to Report Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - The Manila Times
Major Biotech Earnings Alert: Regeneron Pharmaceuticals Q3 2025 Results Coming October 28 Before Market Open - Stock Titan
Regeneron Sues Biosimilar Maker Over IP Rights Exemption - Law360
Regeneron Deal Clears Formycon’s Eylea Biosimilar for Late 2026 - Bloomberg Law News
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):